Scholarlink

Background <p>Knee osteoarthritis (OA) is a common degenerative joint condition for which current treatments primarily provide symptom control without restoring cartilage. Biologic injectables such as platelet-rich plasma (PRP) and adipose-derived cellular preparations have gained interest as potential disease-modifying options. This review compares the current clinical evidence regarding their relative effectiveness.</p> Methods <p>Following PRISMA 2020 guidelines, PubMed, Scopus, Cochrane Library, Europe PMC, and CNKI were searched. Eligible studies were level 1–2 clinical trials directly comparing PRP with adipose-derived cell-based therapies in knee OA. Pain, function, quality of life, sports activity, and complications were assessed. Quality was evaluated using MINORS.</p> Results <p>Three studies (two hundred forty-one knees) were included, all high quality (MINORS 19–24). Both PRP and adipose-derived cell-based therapies significantly improved pain, function, and quality of life with no reported complications. Two studies showed no difference between PRP and microfragmented or autologous adipose tissue (MFAT/AAT) at 6–12&#xa0;months. One study found culture-expanded adipose-derived stem cells (ADSCs) provided greater improvements in pain (WOMAC, VAS), stiffness, and several SF-36 domains compared with PRP at 6&#xa0;months.</p> Conclusion <p>PRP and adipose-derived cell-based therapies are safe and effective for knee OA. PRP offers a minimally invasive, cost-effective option with outcomes comparable to MFAT and AAT. ADSCs may provide superior symptom relief but involve greater complexity and cost. Larger, standardized trials with longer follow-up are needed to confirm long-term efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Outcomes of Adipose-Derived Cell-Based Therapies Versus Platelet-Rich Plasma in Knee Osteoarthritis: A Systematic Review

  • 期刊论文

  • 发表日期：

    2026年1月10日

查看全文
  • Phisitphong Piyapanyamongkhon,
  • Waranyoo Rojpalakorn,
  • Narata Yudtanahiran,
  • Thun Itthipanichpong,
  • Danaithep Limskul,
  • Napatpong Thamrongskulsiri

摘要

Background

Knee osteoarthritis (OA) is a common degenerative joint condition for which current treatments primarily provide symptom control without restoring cartilage. Biologic injectables such as platelet-rich plasma (PRP) and adipose-derived cellular preparations have gained interest as potential disease-modifying options. This review compares the current clinical evidence regarding their relative effectiveness.

Methods

Following PRISMA 2020 guidelines, PubMed, Scopus, Cochrane Library, Europe PMC, and CNKI were searched. Eligible studies were level 1–2 clinical trials directly comparing PRP with adipose-derived cell-based therapies in knee OA. Pain, function, quality of life, sports activity, and complications were assessed. Quality was evaluated using MINORS.

Results

Three studies (two hundred forty-one knees) were included, all high quality (MINORS 19–24). Both PRP and adipose-derived cell-based therapies significantly improved pain, function, and quality of life with no reported complications. Two studies showed no difference between PRP and microfragmented or autologous adipose tissue (MFAT/AAT) at 6–12 months. One study found culture-expanded adipose-derived stem cells (ADSCs) provided greater improvements in pain (WOMAC, VAS), stiffness, and several SF-36 domains compared with PRP at 6 months.

Conclusion

PRP and adipose-derived cell-based therapies are safe and effective for knee OA. PRP offers a minimally invasive, cost-effective option with outcomes comparable to MFAT and AAT. ADSCs may provide superior symptom relief but involve greater complexity and cost. Larger, standardized trials with longer follow-up are needed to confirm long-term efficacy.